Preliminary Acceptability of a Home-Based Peripheral Blood Collection Device for Viral Load Testing in the Context of Analytical Treatment Interruptions in HIV Cure Trials: Results from a Nationwide Survey in the United States

Author:

Dubé KarineORCID,Eskaf ShadiORCID,Hastie ElizabethORCID,Agarwal Harsh,Henley Laney,Roebuck Christopher,Carter William B.,Dee Lynda,Taylor Jeff,Mapp Derrick,Campbell Danielle M.,Villa Thomas J.,Peterson Beth,Lynn Kenneth M.,Lalley-Chareczko Linden,Hiserodt Emily,Kim Sukyung,Rosenbloom Daniel,Evans Brad R.,Anderson Melanie,Hazuda Daria J.,Shipley Lisa,Bateman Kevin,Howell Bonnie J.,Mounzer Karam,Tebas Pablo,Montaner Luis J.

Abstract

Frequent viral load testing is necessary during analytical treatment interruptions (ATIs) in HIV cure-directed clinical trials, though such may be burdensome and inconvenient to trial participants. We implemented a national, cross-sectional survey in the United States to examine the acceptability of a novel home-based peripheral blood collection device for HIV viral load testing. Between June and August 2021, we distributed an online survey to people with HIV (PWH) and community members, biomedical HIV cure researchers and HIV care providers. We performed descriptive analyses to summarize the results. We received 73 survey responses, with 51 from community members, 12 from biomedical HIV cure researchers and 10 from HIV care providers. Of those, 51 (70%) were cisgender men and 50 (68%) reported living with HIV. Most (>80% overall) indicated that the device would be helpful during ATI trials and they would feel comfortable using it themselves or recommending it to their patients/participants. Of the 50 PWH, 42 (84%) indicated they would use the device if they were participating in an ATI trial and 27 (54%) also expressed a willingness to use the device outside of HIV cure studies. Increasing sensitivity of viral load tests and pluri-potency of the device (CD4 count, chemistries) would augment acceptability. Survey findings provide evidence that viral load home testing would be an important adjunct to ongoing HIV cure-directed trials involving ATIs. Survey findings may help inform successful implementation and uptake of the device in the context of personalized HIV care.

Publisher

MDPI AG

Subject

Medicine (miscellaneous)

Reference50 articles.

1. Recommendations for Analytical Antiretroviral Treatment Interruptions in HIV Research Trials—Report of a Consensus Meeting;Lancet HIV,2019

2. TAG (2021, November 29). Research Toward a Cure Trials. Available online: http://www.treatmentactiongroup.org/cure/trials.

3. The need for treatment interruption studies and biomarker identification in the search for an HIV cure;AIDS,2015

4. Phospholipid Metabolism Is Associated with Time to HIV Rebound upon Treatment Interruption;mBio,2021

5. Non-invasive plasma glycomic and metabolic biomarkers of post-treatment control of HIV;Nat. Commun.,2021

Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3